Carotid disease rarely announces itself politely. It may show up as a brief spell of word-finding trouble, a crooked smile in the mirror, or a transient curtain drifting over one eye. Sometimes it gives no warning at all. As a vascular and endovascular surgeon, I spend much of my clinical week weighing two excellent options for stroke prevention in people with carotid artery stenosis: carotid endarterectomy and carotid artery stenting. Both reduce embolic risk from plaque in the neck. Both carry hazards that matter in different patients for different reasons. Matching the right patient to the right approach is the art that sits on top of the science.
The stroke mechanics we are trying to stop
Most ischemic strokes associated with carotid disease are embolic. Plaque builds along the carotid bifurcation, becomes irregular, and sheds debris that travels to the brain. Turbulence at the bifurcation, ulceration of the plaque surface, and superimposed thrombus all raise the odds. Stenosis severity correlates with risk, but morphology and recent symptoms often drive the short-term danger even more. A 60 percent narrowing that produced a retinal transient ischemic attack last week, with a friable plaque cap on duplex ultrasound, may worry me more than an 80 percent narrowing that has been quiet for two years.
From a practical standpoint, there are three levers to pull: optimize medical therapy, choose the right revascularization strategy when indicated, and time the intervention to the phase of risk. The first lever belongs to every circulation specialist involved. The second and third are where a carotid surgeon earns their keep.
What “best medical therapy” means today
We do not operate or stent in a vacuum. Medical therapy has become formidable, and it matters. High-intensity statins, antiplatelet agents, blood pressure control, smoking cessation, diabetes management, and lifestyle changes all reduce stroke risk. Imaging follow-up and patient education make the plan stick.
A typical regimen includes a high-intensity statin aimed at LDL less than 70 mg/dL, aspirin or clopidogrel in most cases, and tighter blood pressure targets than were common a generation ago. Rivaroxaban does not replace antiplatelet therapy for carotid atherosclerosis, but it may be considered in select polyvascular disease, balanced against bleeding risk. For symptomatic patients awaiting carotid revascularization, I am meticulous about adherence and blood pressure control. It is routine for my team’s vascular ultrasound specialist to repeat duplex imaging if the clinical picture changes, and to document plaque features that hint at instability.
Endarterectomy and stenting in plain terms
Carotid endarterectomy is a surgical cleanout. Through a small neck incision, we open the carotid artery, peel out the plaque and its cap, patch the artery to maintain caliber, and close. The procedure removes the embolic source directly. Neuromonitoring, shunting, and meticulous technique limit ischemic time. Most patients go home the next day.
Carotid artery stenting is an endovascular approach. Via the femoral or radial artery, we navigate a catheter to the carotid lesion, cross it with a wire, trap debris with an embolic protection device, and deploy a stent to scaffold the plaque and expand the lumen. Variants include transcarotid artery revascularization, or TCAR, which uses a small incision above the clavicle and a reversal of flow during stent deployment to reduce cerebral embolization.
Both strategies aim at the same endpoint: fewer emboli reaching the brain. They simply get there by different routes, and each brings its own profile of periprocedural risk.
The evidence that shapes everyday choices
Trials have been run and scrutinized for decades. When you strip away the acronyms and subgroup arguments, a few themes hold steady and align with everyday practice.
Carotid endarterectomy remains the reference standard for many symptomatic patients. In men with recent hemispheric symptoms and severe stenosis, surgery offers a durable stroke risk reduction when performed promptly, ideally within two weeks of the last event. The sooner you remove a culprit plaque, the fewer emboli it can shed. Women with severe symptomatic stenosis benefit as well, although the margin can be narrower, so surgeon experience, plaque features, and comorbidities weigh more.
Carotid artery stenting performs well in anatomically or medically high-risk surgical candidates, and in the hands of experienced operators using contemporary techniques. The learning curve and protection strategy matter. TCAR in particular has helped close the gap by reducing embolic load during the critical moments of crossing and deployment.
Age consistently influences the calculus. In most datasets, periprocedural stroke risk with transfemoral stenting increases with age, especially beyond 70 to 75, while surgical risk rises more modestly with age. That tilt makes me favor endarterectomy in older symptomatic patients, provided the neck is approachable and cardiac risk acceptable. In younger patients with favorable arch anatomy, stenting can be quite competitive.
Neck anatomy is not a footnote. A hostile arch with shaggy atheroma, severe tortuosity, or a Type III takeoff can turn a stenting case into an embolic minefield. A high carotid bifurcation tucked under the jaw, prior neck radiation, or a reoperative scar can turn a straightforward endarterectomy into a cranial nerve hazard. TCAR helps bridge some of these anatomic divides by avoiding the aortic arch and shortening the path.
How I decide with a patient in front of me
Picture a 74-year-old man, former smoker, on high-intensity statin and aspirin, who developed transient weakness in his right hand and expressive aphasia for 15 minutes two days ago. Duplex shows 80 percent left internal carotid stenosis with an irregular plaque. His heart looks reasonable on echo, and his risk for general anesthesia is moderate. In this patient, time is the enemy. I favor carotid endarterectomy in the next several days, assuming no evolving deficits and no significant cardiac contraindication. The plaque is the culprit, the neck is likely approachable, and surgical removal minimizes embolic risk during the intervention.
Now consider a 67-year-old woman with prior neck radiation for lymphoma, a short stiff neck, and a high carotid bifurcation. She has 75 percent asymptomatic stenosis discovered on screening during coronary workup. In her case, stenting can spare cranial nerves and a difficult dissection. I would discuss TCAR because it sidesteps the arch and keeps embolic load low. We would also weigh whether she needs revascularization at all, given that asymptomatic patients have lower annual stroke risk on today’s medical therapy. Plaque morphology and life expectancy tip the scale.
I also see a steady stream of octogenarians referred for “severe stenosis.” Blanket rules serve them poorly. An 84-year-old who golfs three times a week, drives, and suffered amaurosis fugax last month may gain from an operation. An 84-year-old with advanced dementia and frailty will not. Stroke prevention must mean prevention of stroke that matters to that person’s remaining years, not pursuit of a perfect angiogram.
What risks patients actually feel
Most patients want to understand the hazards in straight language, not composite endpoints. With endarterectomy, the upfront risks are stroke, heart attack, and cranial nerve injury. The stroke risk is low in experienced hands, usually in the low single digits, and often lower than stenting in older symptomatic patients. Heart attack risk is tied to anesthesia and baseline coronary disease. Cranial nerve issues, when they occur, are usually temporary hoarseness, tongue weakness, or lower lip numbness. Long-term, restenosis can occur, but symptomatic recurrence is uncommon when the plaque is excised and the artery patched.
With stenting, the upfront hazard concentrates around emboli released during catheter manipulation and stent deployment. Modern protection devices help but do not erase the risk, and the risk tends to rise with age and hostile arch anatomy. Access site bleeding, especially with dual antiplatelet therapy, is a realistic inconvenience. Long-term, stents can restenose due to intimal hyperplasia. That risk appears higher in some subgroups than patch angioplasty restenosis after surgery, though monitoring and touch-up angioplasty can manage it.
Patients ask about anesthesia. Endarterectomy uses general or regional anesthesia. In many centers, awake CEA with cervical block allows direct neurologic monitoring and avoids intubation, which helps patients with marginal lungs. Stenting is almost always under local with light sedation. For some people, avoidance of a general anesthetic is a meaningful benefit.
Symptomatic versus asymptomatic: two different conversations
The benefit of revascularization is largest and clearest in symptomatic severe stenosis, particularly within the first two weeks after a TIA or minor stroke. Waiting until the plaque quiets can squander the highest-risk window. The choice then centers on the approach.
Asymptomatic stenosis is more nuanced. With widespread statin use, better blood pressure control, and more consistent antiplatelet therapy, the annual ipsilateral stroke risk for many asymptomatic patients has fallen. Some will never suffer a stroke from that lesion. That is not a reason to ignore the carotid, but it is a reason to individualize. Indicators that push me toward revascularization in asymptomatic cases include very high-grade stenosis with rapid progression, microemboli on transcranial Doppler, plaque ulceration, contralateral occlusion, or need for open heart surgery where perioperative stroke risk could be lowered by addressing the carotid first. If we proceed, method selection returns to the same anatomy, age, and comorbidity Milford vascular surgeon assessment.
TCAR: a practical middle path
Transcarotid artery revascularization deserves its own paragraph because it occupies a useful middle ground. The small incision above the clavicle lets me place a sheath directly into the carotid and establish flow reversal through a filtered circuit during stenting. That reversal catches debris before it can ascend to the brain. By avoiding the aortic arch, TCAR reduces the risk inherent in navigating wires and catheters past atheroma in elderly patients. For many older symptomatic patients with reasonable neck anatomy but high arch risk, TCAR narrows the outcome differences with endarterectomy while keeping cranial nerve risk low. It is not a universal fix, and it still requires dual antiplatelet therapy and careful technique, but it has expanded the endovascular surgeon’s toolkit in a way that genuinely helps patients.
What imaging tells me, and what it does not
Duplex ultrasound anchors our assessment. A good vascular ultrasound specialist can characterize peak systolic velocities, end-diastolic flow, plaque morphology, and oddities like string sign or near-occlusion. I look for ulceration, echolucent lipid-rich areas, and thrombus. Computed tomography angiography adds lumen detail, arch anatomy, calcification burden, and helps plan whether a high bifurcation might complicate an open approach. Magnetic resonance angiography is an option when iodinated contrast is risky, though it can overestimate stenosis and is less helpful for calcium. Catheter angiography is now mainly a procedural step rather than a diagnostic one.
Imaging does not tell me how a patient values their voice if a temporary vocal cord palsy occurs, or how comfortable they feel about the idea of a neck incision versus a stent. It does not tell me whether a patient can adhere to dual antiplatelet therapy after stenting, which is non-negotiable in the short term. Those are conversations, not scans.
Timing and team logistics
Speed matters after symptoms. I structure my practice to offer urgent surgery for the right candidate within days, not weeks, and the same goes for stenting or TCAR when that path is chosen. That means tight coordination with neurologists, hospitalists, and our operating room team. Antiplatelet management is planned carefully. For endarterectomy, I usually continue aspirin. For stenting or TCAR, dual antiplatelet therapy is started promptly, often with a loading dose. If a patient presents on anticoagulation, we plan a safe bridge or, if stroke risk is pressing, determine whether local anesthesia and minimally invasive technique can avoid prolonged interruption.
Real-world trade-offs that rarely fit in a table
Anticoagulation complicates both paths. A patient with a mechanical valve on warfarin who needs symptomatic carotid intervention triggers a chain of decisions about bridging, bleeding risk, and whether the neurologic presentation suggests plaque emboli or a cardioembolic source. If the carotid lesion is clearly culpable, I still favor endarterectomy for many such patients because I can often proceed on aspirin with minimal interruption of anticoagulation, whereas stenting demands dual antiplatelet therapy and introduces another antithrombotic agent to juggle.
Severe chronic obstructive pulmonary disease nudges toward stenting or TCAR, since avoiding general anesthesia and a neck dissection lowers pulmonary risk. Yet I have operated comfortably on many advanced COPD patients using a cervical block and careful monitoring, with the patient chatting through the case and walking later that afternoon. The team’s comfort with regional anesthesia and awake neurologic monitoring changes the equation.
Prior neck surgery or radiation usually favors stenting or TCAR to avoid cranial nerve injury and poor wound healing. Dense calcification at the bifurcation sometimes leans me back toward surgery, especially if I worry that an unyielding plaque will not expand well and may fracture in a way that invites embolization despite protection.
Outcomes that matter over five years, not just 30 days
The first 30 days after any carotid intervention draw the headlines. But what patients live with is the next five to ten years. After a successful endarterectomy with patch angioplasty, stroke rates remain low, and restenosis, if it occurs, is often hemodynamically mild. After stenting, freedom from restenosis depends on lesion biology and patient factors like smoking and diabetes. When restenosis does occur, it is commonly managed percutaneously with angioplasty, sometimes with a drug-coated balloon, and less often with redo stenting or surgery.
Long-term antiplatelet therapy differs slightly. Post-endarterectomy, single antiplatelet therapy is standard for most. Post-stenting, dual antiplatelet therapy for a period is followed by long-term single therapy. Medication adherence therefore has more weight in stenting decisions. A patient with unreliable follow-up or frequent falls and bruising may be better served by an operation that keeps antithrombotic requirements lighter after the early phase.
How to think about finding the right operator
In many regions, you will find a vascular and endovascular surgeon who does both operations. That breadth helps because there is no incentive to steer you toward one pathway. A board certified vascular surgeon who can share their personal stroke and nerve injury rates for endarterectomy, and their stroke and access complication rates for stenting or TCAR, is who you want. Ask how frequently they perform each procedure, how they decide between them, and what your imaging shows beyond the percentage number. An experienced vascular surgeon near me is not simply the closest one, but the one who can articulate risks and plan, not just recite them.
Patients often search terms like carotid surgeon, artery specialist, vascular medicine specialist, or circulation doctor and arrive in a clinic unsure if they need an interventional vascular surgeon or a vascular radiologist. Do not worry about the label. Worry about the team’s outcomes, transparency, and coordination with your neurologist and primary care physician. The same heuristic applies for any related vascular condition you might carry, whether you are seeing a PAD doctor for claudication or a DVT specialist for venous issues. Subspecialty fluency helps, but habit and volume matter just as much.
A brief note on cost, recovery, and daily life
Most insured patients have similar out-of-pocket obligations for endarterectomy, stenting, and TCAR. The differences that patients feel are in recovery details. After endarterectomy, expect a sore neck for several days, a small scar low on the side of the neck, and a restriction on heavy lifting for roughly a week. After stenting or TCAR, expect a tender access site at the groin, wrist, or just above the clavicle, and a stronger emphasis on avoiding bleeding while on dual antiplatelet therapy. Both approaches typically send you home the next day. Most people resume light activity immediately and normal routines inside a week. Driving follows neurologic stability and surgeon advice.
When no intervention is the best intervention
There is a quiet victory in telling someone that their risk is low enough on medical therapy that we should watch and wait. A 65-year-old with 60 percent asymptomatic stenosis on serial ultrasounds that have not budged in three years, on high-intensity statin, with blood pressure at goal and no smoking, often lands here. We schedule ultrasound surveillance, refine risk factors, and move on with life. Not every stenosis demands a knife or a stent. Over-treating arteries that are not misbehaving can cause harm, and humility is part of being a vascular disease specialist.
The minimalist comparison patients ask for
- Endarterectomy: excellent stroke prevention in symptomatic severe stenosis, especially in older patients; modest risk of cranial nerve injury and heart events; general or regional anesthesia; usually single antiplatelet therapy long term. Stenting or TCAR: less invasive; avoids neck dissection; better fit for hostile necks or high surgical risk; higher periprocedural stroke risk with transfemoral stenting in older patients, mitigated by TCAR; dual antiplatelet therapy required short term.
What to do if you or a family member has a new TIA
- Seek urgent evaluation. Do not wait for an outpatient referral to a vein doctor or a general clinic. A blood vessel doctor experienced in carotid disease should see you quickly. Get the right imaging. A high-quality duplex ultrasound and either CTA or MRA clarify anatomy and urgency. Start or optimize medical therapy immediately. High-intensity statin and antiplatelet therapy make a difference even before a procedure. Discuss timing. If revascularization is indicated, aim for days, not weeks, after a minor stroke or TIA, assuming stability. Choose the approach that fits your anatomy, age, and comorbidities, not the one that fits a clinic’s habit.
Final perspective from the operating room and the angio suite
The decision between endarterectomy and stenting is not a referendum on technology or tradition. It is a problem of risk transfer: do you accept the embolic risk of crossing a lesion with wires to avoid an incision, or do you accept a neck incision and a brief clamp time to remove the problem at its source? The right answer shifts with age, arch anatomy, neck history, symptoms, medication needs, and the operator’s experience.
I have seen endarterectomies transform a ragged, ulcerated bifurcation into a smooth channel with a patch that looks better than any stent could manage. I have also watched TCAR rescue an elderly patient from the hazards of a hostile arch while giving them a quick recovery and a clean duplex at six months. Both moments are satisfying because they reflect a tailored decision rather than a reflex.
If you are reading this as someone newly told you have a blocked carotid, take heart. Between today’s medical therapy and skilled revascularization, your odds are good. Find an experienced vascular and endovascular surgeon who can walk you through your images, put numbers to your risks, and make a recommendation that accounts for your priorities. The best vascular surgery specialist is the one who sees you as more than a percentage on a scan, and who is comfortable with the scalpel and the stent but beholden to neither.
